Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Pharmacokinetic Study of Nifedipine in Healthy Adult Male Human Volunteers

M Ahmad1 , T Ahmad2, R A Sultan3, G Murtaza1

1Department of Pharmacy, Faculty of Pharmacy and Alternative Medicines, The Islamia University of Bahawalpur, Bahawalpur 63100; 2HEJ Research Institute of Chemistry, University of Karachi, Karachi; 3Faculty of Pharmacy, University of Karachi, Karachi, Pakistan.

For correspondence:-  M Ahmad   Email: ma786_786@yahoo.com   Tel:+92629255243

Received: 2 February 2009        Accepted: 12 June 2009        Published: 23 October 2009

Citation: Ahmad M, Ahmad T, Sultan RA, Murtaza G. Pharmacokinetic Study of Nifedipine in Healthy Adult Male Human Volunteers. Trop J Pharm Res 2009; 8(5):385-391 doi: 10.4314/tjpr.v8i5.2

© 2009 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the pharmacokinetics of nifedipine in healthy adult Pakistani subjects.
Methods: Each of six fasting volunteers received 20 mg nifedipine (2 x Adalat® 10 mg capsules) orally once and then another one week later. Their blood samples were obtained at regular time intervals and analysed by HPLC. Using the non-compartmental approach, plasma levels of nifedipine were employed to compute their individual disposition kinetics, including Cmax (maximum plasma concentration), Tmax (time to reach maximum plasma concentration), MRT (mean residence time), AUC0-∞ (area under curve), AUMC0-∞ (area under first moment curve) and Ka (absorption rate constant).
Results: The suggested therapeutic level of nifedipine for the treatment of hypertension (15-35 ng.mL-1) was achieved in all six volunteers within 0.25 h after dose administration, and maintained for more than 6 h. Tmax was 1.58 h and Cmax varied from 140 – 300 ng.mL-1. Mean absorption rate constant was 2.22 h-1 while mean absorption half-life was 0.43 h. The mean elimination rate constant was 0.16 h-1 while 5.7 h was recorded for terminal half-life. AUC0-¥, AUMC0-¥ and MRT were 1879.86 ng.h.mL-1, 8244.04 ng.h2.mL-1 and 4.2 h, respectively.
Conclusion: This study confirms the rapid absorption of nifedipine in humans. AUC was similar to that previously reported for Nigerians but slightly lower than that stated in the literature for other south Asian races. Further studies on large segments of the local population using the non-compartmental model for kinetic analysis is recommended.

Keywords: Nifedipine; Pharmacokinetics; Non-compartmental model; Pakistani subjects

Impact Factor
Thompson Reuters (ISI): 0.523 (2021)
H-5 index (Google Scholar): 39 (2021)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates